Iuvantium is a deep-tech synthetic immunobiology company that develops inorganic immune modulators to enhance the efficacy and customization of immunotherapies and vaccines. By leveraging materials science and translational immunology, the company addresses the limitations in current cancer and infectious disease treatments, enabling scalable and cost-effective therapeutic solutions.
Funding
Funding not disclosed
Founders
Product
Problem
Current immunotherapies and vaccines face limitations in efficacy, customization, scalability, and cost-effectiveness, hindering their ability to effectively treat cancer and infectious diseases. Existing treatments often lack the flexibility to be tailored to specific diseases or antigen platforms, resulting in suboptimal immune responses.
Solution
Iuvantium is developing inorganic immune modulators to enhance and customize immunotherapies and vaccines. By applying materials science, translational immunology, and complex systems engineering, Iuvantium aims to create a new modality of inorganic immune modulators that elicit predictable immune responses. Their platform enables immunotherapy developers to improve the performance and accessibility of their formulations, leading to more effective treatments for cancer and infectious diseases. The technology aspires to deliver a highly flexible immunomodulator platform, which unlocks the full potential for each therapy and enables optimization and complete customization of therapeutic and vaccine formulations.
Target Audience
The primary target audience includes immunotherapy developers and pharmaceutical companies seeking to enhance the effectiveness and accessibility of their vaccine and drug formulations.
Features
- Nanomaterials-based immunomodulators with compositional freedom and control of physicochemical properties
- Customizable immunomodulator system tailored to the targeted disease and/or antigen platform
- Platform enables administration in liquid or dry state
- Agnostic to type of therapy
- prophylactic or therapeutic